BridGene Biosciences

BridGene Biosciences is a biotechnology company dedicated to discovering and developing innovative small molecules that target traditionally "undruggable" targets, offering new avenues for disease treatment. Utilizing its proprietary chemoproteomics platform, IMTAC™, the company screens small molecules against all proteins in living cells to identify drug candidates for high-value but previously undruggable targets. The ultimate goal is to enable the discovery of highly selective and effective small-molecule drugs and expand the mechanisms for treating diseases, as traditional small molecules were unable to reach these targets. The company is advancing a diversified pipeline of first-in-class drugs targeting multiple therapeutic areas.